Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
23 sept. 2024 07h00 HE
|
Skye Bioscience, Inc.
16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule...
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
03 sept. 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
26 août 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23 août 2024 18h45 HE
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
22 août 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
09 août 2024 17h59 HE
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways...
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
24 juil. 2024 06h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
11 juil. 2024 07h15 HE
|
Skye Bioscience, Inc.
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
11 juil. 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
03 juil. 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and...